BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rieder F, de Bruyn JR, Pham BT, Katsanos K, Annese V, Higgins PD, Magro F, Dotan I. Results of the 4th scientific workshop of the ECCO (Group II): markers of intestinal fibrosis in inflammatory bowel disease. J Crohns Colitis. 2014;8:1166-1178. [PMID: 24726695 DOI: 10.1016/j.crohns.2014.03.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Vieujean S, Loly JP, Boutaffala L, Meunier P, Reenaers C, Briquet A, Lechanteur C, Baudoux E, Beguin Y, Louis E. Mesenchymal Stem Cell Injection in Crohn's Disease Strictures: a phase I-II clinical study. J Crohns Colitis 2021:jjab154. [PMID: 34473270 DOI: 10.1093/ecco-jcc/jjab154] [Reference Citation Analysis]
2 Mantaka A, Tsoukali E, Fragkaki M, Karmiris K, Viazis N, Mantzaris GJ, Koutroubakis IE. Is there any role of renin-angiotensin system inhibitors in modulating inflammatory bowel disease outcome? Eur J Gastroenterol Hepatol 2021;33:364-71. [PMID: 32925506 DOI: 10.1097/MEG.0000000000001912] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 He JS, Tan JY, Li XZ, Feng R, Xiong SS, Lin SN, Qiu Y, Mao R. Serum biomarkers of fibrostenotic Crohn's disease: Where are we now? J Dig Dis 2020;21:336-41. [PMID: 32496631 DOI: 10.1111/1751-2980.12913] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Vieujean S, Hu S, Bequet E, Salee C, Massot C, Bletard N, Pierre N, Quesada Calvo F, Baiwir D, Mazzucchelli G, De Pauw E, Coimbra Marques C, Delvenne P, Rieder F, Louis E, Meuwis MA. Potential Role of Epithelial Endoplasmic Reticulum Stress and Anterior Gradient Protein 2 Homolog in Crohn's Disease Fibrosis. J Crohns Colitis 2021:jjab061. [PMID: 33822017 DOI: 10.1093/ecco-jcc/jjab061] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
5 Derkacz A, Olczyk P, Olczyk K, Komosinska-Vassev K. The Role of Extracellular Matrix Components in Inflammatory Bowel Diseases. J Clin Med 2021;10:1122. [PMID: 33800267 DOI: 10.3390/jcm10051122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
6 Shimshoni E, Adir I, Afik R, Solomonov I, Shenoy A, Adler M, Puricelli L, Sabino F, Savickas S, Mouhadeb O, Gluck N, Fishman S, Werner L, Salame TM, Shouval DS, Varol C, Auf dem Keller U, Podestà A, Geiger T, Milani P, Alon U, Sagi I. Distinct extracellular-matrix remodeling events precede symptoms of inflammation. Matrix Biol 2021;96:47-68. [PMID: 33246101 DOI: 10.1016/j.matbio.2020.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
7 Gundersen MD, Goll R, Fenton CG, Anderssen E, Sørbye SW, Florholmen JR, Paulssen RH. Fibrosis Mediators in the Colonic Mucosa of Acute and Healed Ulcerative Colitis. Clin Transl Gastroenterol 2019;10:e00082. [PMID: 31584460 DOI: 10.14309/ctg.0000000000000082] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
8 Le Fur M, Zhou IY, Catalano O, Caravan P. Toward Molecular Imaging of Intestinal Pathology. Inflamm Bowel Dis 2020;26:1470-84. [PMID: 32793946 DOI: 10.1093/ibd/izaa213] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Caruso A, Angriman I, Scarpa M, D'Incà R, Mescoli C, Rudatis M, Sturniolo GC, Schifano G, Lacognata C. Diffusion-weighted magnetic resonance for assessing fibrosis in Crohn's disease. Abdom Radiol (NY) 2020;45:2327-35. [PMID: 31392397 DOI: 10.1007/s00261-019-02167-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
10 Chen P, Zhou G, Lin J, Li L, Zeng Z, Chen M, Zhang S. Serum Biomarkers for Inflammatory Bowel Disease. Front Med (Lausanne). 2020;7:123. [PMID: 32391365 DOI: 10.3389/fmed.2020.00123] [Cited by in Crossref: 19] [Cited by in F6Publishing: 35] [Article Influence: 9.5] [Reference Citation Analysis]
11 Pellino G, Keller DS, Sampietro GM, Annese V, Carvello M, Celentano V, Coco C, Colombo F, Cracco N, Di Candido F, Franceschi M, Laureti S, Mattioli G, Pio L, Sciaudone G, Sica G, Villanacci V, Zinicola R, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F;  the Italian Society of Colorectal Surgery (SICCR). Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management. Tech Coloproctol. 2020;24:105-126. [PMID: 31983044 DOI: 10.1007/s10151-019-02145-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
12 Bokemeyer A, Tepasse PR, Quill L, Lenz P, Rijcken E, Vieth M, Ding N, Ketelhut S, Rieder F, Kemper B, Bettenworth D. Quantitative Phase Imaging Using Digital Holographic Microscopy Reliably Assesses Morphology and Reflects Elastic Properties of Fibrotic Intestinal Tissue. Sci Rep 2019;9:19388. [PMID: 31852983 DOI: 10.1038/s41598-019-56045-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
13 Li XH, Fang ZN, Guan TM, Lin JJ, Sun CH, Huang SY, Mao R, Lu BL, Cao QH, Feng ST, Li ZP. A novel collagen area fraction index to quantitatively assess bowel fibrosis in patients with Crohn's disease. BMC Gastroenterol 2019;19:180. [PMID: 31711420 DOI: 10.1186/s12876-019-1100-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
14 Li Yim AYF, de Bruyn JR, Duijvis NW, Sharp C, Ferrero E, de Jonge WJ, Wildenberg ME, Mannens MMAM, Buskens CJ, D'Haens GR, Henneman P, Te Velde AA. A distinct epigenetic profile distinguishes stenotic from non-inflamed fibroblasts in the ileal mucosa of Crohn's disease patients. PLoS One 2018;13:e0209656. [PMID: 30589872 DOI: 10.1371/journal.pone.0209656] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
15 Zhang M, Li X, Huang S, Mao R, Fang Z, Cao Q, Zhang Z, Yan X, Chen M, Li Z, Sun C, Feng S. IVIM with fractional perfusion as a novel biomarker for detecting and grading intestinal fibrosis in Crohn’s disease. Eur Radiol 2019;29:3069-78. [DOI: 10.1007/s00330-018-5848-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
16 Pierdomenico M, Palone F, Cesi V, Vitali R, Mancuso AB, Cucchiara S, Oliva S, Aloi M, Stronati L. Transcription Factor ZNF281: A Novel Player in Intestinal Inflammation and Fibrosis. Front Immunol 2018;9:2907. [PMID: 30619271 DOI: 10.3389/fimmu.2018.02907] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
17 Ballengee CR, Stidham RW, Liu C, Kim MO, Prince J, Mondal K, Baldassano R, Dubinsky M, Markowitz J, Leleiko N, Hyams J, Denson L, Kugathasan S. Association Between Plasma Level of Collagen Type III Alpha 1 Chain and Development of Strictures in Pediatric Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2019;17:1799-806. [PMID: 30213581 DOI: 10.1016/j.cgh.2018.09.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
18 Wilkens R, Hagemann-Madsen RH, Peters DA, Nielsen AH, Nørager CB, Glerup H, Krogh K. Validity of Contrast-enhanced Ultrasonography and Dynamic Contrast-enhanced MR Enterography in the Assessment of Transmural Activity and Fibrosis in Crohn's Disease. J Crohns Colitis 2018;12:48-56. [PMID: 28981627 DOI: 10.1093/ecco-jcc/jjx111] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 11.8] [Reference Citation Analysis]
19 Rieder F, Bettenworth D, Ma C, Parker CE, Williamson LA, Nelson SA, van Assche G, Di Sabatino A, Bouhnik Y, Stidham RW, Dignass A, Rogler G, Taylor SA, Stoker J, Rimola J, Baker ME, Fletcher JG, Panes J, Sandborn WJ, Feagan BG, Jairath V. An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease. Aliment Pharmacol Ther 2018;48:347-57. [PMID: 29920726 DOI: 10.1111/apt.14853] [Cited by in Crossref: 98] [Cited by in F6Publishing: 91] [Article Influence: 24.5] [Reference Citation Analysis]
20 Lian L, Huang Q, Zhang L, Qin H, He X, He X, Ke J, Xie M, Lan P. Anti-fibrogenic Potential of Mesenchymal Stromal Cells in Treating Fibrosis in Crohn’s Disease. Dig Dis Sci 2018;63:1821-34. [DOI: 10.1007/s10620-018-5082-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
21 Hussey GS, Cramer MC, Badylak SF. Extracellular Matrix Bioscaffolds for Building Gastrointestinal Tissue. Cell Mol Gastroenterol Hepatol 2018;5:1-13. [PMID: 29276748 DOI: 10.1016/j.jcmgh.2017.09.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
22 Valatas V, Filidou E, Drygiannakis I, Kolios G. Stromal and immune cells in gut fibrosis: the myofibroblast and the scarface. Ann Gastroenterol 2017;30:393-404. [PMID: 28655975 DOI: 10.20524/aog.2017.0146] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
23 Suzuki K, Yoneyama H. New endoscopic approach of anti-fibrotic therapy for inflammatory bowel disease. Ann Transl Med 2017;5:191. [PMID: 28616406 DOI: 10.21037/atm.2017.03.65] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
24 Colombel JF, Mahadevan U. Inflammatory Bowel Disease 2017: Innovations and Changing Paradigms. Gastroenterology 2017;152:309-12. [PMID: 27960091 DOI: 10.1053/j.gastro.2016.12.004] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
25 Rieder F, Fiocchi C, Rogler G. Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017;152:340-350.e6. [PMID: 27720839 DOI: 10.1053/j.gastro.2016.09.047] [Cited by in Crossref: 163] [Cited by in F6Publishing: 193] [Article Influence: 27.2] [Reference Citation Analysis]
26 Magarotto A, Orlando S, Coletta M, Conte D, Fraquelli M, Caprioli F. Evolving roles of cross-sectional imaging in Crohn's disease. Digestive and Liver Disease 2016;48:975-83. [DOI: 10.1016/j.dld.2016.05.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
27 Pellino G, Pallante P, Selvaggi F. Novel biomarkers of fibrosis in Crohn’s disease. World J Gastrointest Pathophysiol 2016; 7(3): 266-275 [PMID: 27574564 DOI: 10.4291/wjgp.v7.i3.266] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
28 Pellino G, Marcellinaro R, Sciaudone G, Reginelli A, Esposito P, Riegler G, Canonico S, Villanacci V, Selvaggi F. Large bowel cancer in the setting of inflammatory bowel disease: Features and management with a focus on rectal cancer. Eur Surg 2016;48:191-202. [DOI: 10.1007/s10353-016-0434-0] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
29 Rieder F. Toward an antifibrotic therapy for inflammatory bowel disease. United European Gastroenterol J 2016;4:493-5. [PMID: 27536358 DOI: 10.1177/2050640616660000] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
30 de Bruyn M, Vandooren J, Ugarte-berzal E, Arijs I, Vermeire S, Opdenakker G. The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases. Critical Reviews in Biochemistry and Molecular Biology 2016;51:295-358. [DOI: 10.1080/10409238.2016.1199535] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
31 Kadir S, Wenzel Kragstrup T, Dige A, Kok Jensen S, Dahlerup JF, Kelsen J. Pirfenidone inhibits the proliferation of fibroblasts from patients with active Crohn’s disease. Scandinavian Journal of Gastroenterology 2016;51:1321-5. [DOI: 10.1080/00365521.2016.1185146] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
32 Zidar N, Boštjančič E, Jerala M, Kojc N, Drobne D, Štabuc B, Glavač D. Down-regulation of microRNAs of the miR-200 family and up-regulation of Snail and Slug in inflammatory bowel diseases - hallmark of epithelial-mesenchymal transition. J Cell Mol Med 2016;20:1813-20. [PMID: 27113480 DOI: 10.1111/jcmm.12869] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
33 Giuffrida P, Pinzani M, Corazza GR, Di Sabatino A. Biomarkers of intestinal fibrosis - one step towards clinical trials for stricturing inflammatory bowel disease. United European Gastroenterol J 2016;4:523-30. [PMID: 27536362 DOI: 10.1177/2050640616640160] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
34 Ippolito C, Colucci R, Segnani C, Errede M, Girolamo F, Virgintino D, Dolfi A, Tirotta E, Buccianti P, Di Candio G, Campani D, Castagna M, Bassotti G, Villanacci V, Blandizzi C, Bernardini N. Fibrotic and Vascular Remodelling of Colonic Wall in Patients with Active Ulcerative Colitis. J Crohns Colitis 2016;10:1194-204. [PMID: 26995183 DOI: 10.1093/ecco-jcc/jjw076] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
35 Rieder F, Latella G, Magro F, Yuksel ES, Higgins PDR, Di Sabatino A, de Bruyn JR, Rimola J, Brito J, Bettenworth D, van Assche G, Bemelman W, d’Hoore A, Pellino G, Dignass AU. European Crohn’s and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn’s Disease. ECCOJC 2016;10:873-85. [DOI: 10.1093/ecco-jcc/jjw055] [Cited by in Crossref: 102] [Cited by in F6Publishing: 121] [Article Influence: 17.0] [Reference Citation Analysis]
36 Bettenworth D, Nowacki TM, Cordes F, Buerke B, Lenze F. Assessment of stricturing Crohn's disease: Current clinical practice and future avenues. World J Gastroenterol 2016; 22(3): 1008-1016 [PMID: 26811643 DOI: 10.3748/wjg.v22.i3.1008] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
37 Pellino G, Nicolai E, Catalano OA, Campione S, D'Armiento FP, Salvatore M, Cuocolo A, Selvaggi F. PET/MR Versus PET/CT Imaging: Impact on the Clinical Management of Small-Bowel Crohn's Disease. J Crohns Colitis 2016;10:277-85. [PMID: 26574490 DOI: 10.1093/ecco-jcc/jjv207] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 7.1] [Reference Citation Analysis]
38 Pellino G, Selvaggi F, Ghezzi G, Corona D, Riegler G, Delaini GG. A think tank of the Italian society of colorectal surgery (SICCR) on the surgical treatment of inflammatory bowel disease using the Delphi method: Crohn's disease. Tech Coloproctol 2015;19:639-51. [PMID: 26403232 DOI: 10.1007/s10151-015-1368-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
39 Latella G, Di Gregorio J, Flati V, Rieder F, Lawrance IC. Mechanisms of initiation and progression of intestinal fibrosis in IBD. Scand J Gastroenterol. 2015;50:53-65. [PMID: 25523556 DOI: 10.3109/00365521.2014.968863] [Cited by in Crossref: 80] [Cited by in F6Publishing: 90] [Article Influence: 11.4] [Reference Citation Analysis]
40 Latella G, Rieder F. Time to Look Underneath the Surface: Ulcerative Colitis-Associated Fibrosis. J Crohns Colitis. 2015;9:941-942. [PMID: 26303632 DOI: 10.1093/ecco-jcc/jjv142] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
41 Shimshoni E, Yablecovitch D, Baram L, Dotan I, Sagi I. ECM remodelling in IBD: innocent bystander or partner in crime? The emerging role of extracellular molecular events in sustaining intestinal inflammation. Gut 2015;64:367-72. [PMID: 25416065 DOI: 10.1136/gutjnl-2014-308048] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 9.7] [Reference Citation Analysis]